Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

U of M researchers identify genetic variation behind acute myeloid leukemia treatment success

27.02.2013
Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents.

Their study is published today in Clinical Cancer Research.

In the latest study, U of M researchers evaluated how inherited genetic polymorphisms in CD33, a protein that naturally occurs in most leukemia cells, could affect clinical outcomes of patients treated with an existing chemotherapy drug, gemtuzumab ozogamicin (GO), an immuno-conjugate between anti-CD33 antibody and a cytotoxin known as calicheamicin, which binds to CD33 on leukemic cells. As GO is internalized by leukemia cells, the cytotoxin is released, causing DNA damage and generating leukemic cell death.

In recent clinical trials GO has been shown to induce remission and improve survival in subset of patients with AML, however there is wide inter-patient variation in response.

Jatinder Lamba, Ph.D., and colleagues identified and evaluated three genetic variations of CD33 in two groups of patients with pediatric AML – one group that received the drug GO, and one group that did not. They found that specific genetic variation in CD33 that significantly affected the clinical outcome of AML patients who received GO based chemotherapy.

"Understanding how genetics play a role in how drugs work is extremely useful, particularly for a drug like GO which has shown a very heterogeneous response in AML patients," said Jatinder Lamba, Ph.D., the study's lead author and a researcher who holds appointments in both the College of Pharmacy and the Masonic Cancer Center, University of Minnesota. "Our latest findings lead us to believe that genetic variation in CD33 influences how AML patients' leukemic cell responds to GO."

AML is a cancer of the blood and bone marrow, and is the second most common form of leukemia in children. Though the most common type of treatment for AML is chemotherapy, Lamba says the disease remains hard to treat and newer, more effective therapies are needed.

"The overall goal of our study was to use genetic data to predict beneficial or adverse response to a specific drug, thus opening up opportunities to use this information for drug optimization to achieve maximum therapeutic efficacy and minimum toxicity. Our hope is that our research could serve as a marker of prognostic significance for clinicians to select the therapy that has the greatest odds of being effective for individual patients based on their CD33 genotype."

Other University of Minnesota researchers involved in the study include Leslie Mortland, M.D., from the University of Minnesota Medical School and Betsy Hirsch, Ph.D., from the Medical School and the Masonic Cancer Center, University of Minnesota.

The University of Minnesota College of Pharmacy, the only school of pharmacy in Minnesota, offers its program on the Twin Cities and Duluth campuses. Founded in 1892, the College of Pharmacy educates pharmacists and scientists and engages in research and practice to improve the health of the people of Minnesota and society. The college is part of the Academic Health Center, which is home to the University of Minnesota's six health professional schools and colleges as well as several health-related centers and institutes. Learn more at www.pharmacy.umn.edu.

The University of Minnesota Medical School, with its two campuses in the Twin Cities and Duluth, is a leading educator of the next generation of physicians. Our graduates and the school's 3,800 faculty physicians and scientists advance patient care, discover biomedical research breakthroughs with more than $180 million in sponsored research annually, and enhance health through world-class patient care for the state of Minnesota and beyond. Visit www.med.umn.edu to learn more.

Masonic Cancer Center, University of Minnesota is part of the University's Academic Health Center. It is designated by the National Cancer Institute as a Comprehensive Cancer Center. For more information about the Masonic Cancer Center, visit www.cancer.umn.edu or call 612-624-2620.

Amy Leslie | EurekAlert!
Further information:
http://www.umn.edu

More articles from Life Sciences:

nachricht Genetic Regulation of the Thymus Function Identified
23.08.2016 | Universität Basel

nachricht Sun protection for plants - Plant substances can protect plants against harmful UV radiation
22.08.2016 | Max-Planck-Institut für Molekulare Pflanzenphysiologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Mikroskopieren mit einzelnen Ionen

Neuartiges Ionenmikroskop nutzt einzelne Ionen, um Abbildungen mit einer Auflösung im Nanometerbereich zu erzeugen

Wissenschaftler um Georg Jacob von der Johannes Gutenberg-Universität Mainz haben ein Ionenmikroskop entwickelt, das nur mit exakt einem Ion pro Bildpixel...

Im Focus: Streamlining accelerated computing for industry

PyFR code combines high accuracy with flexibility to resolve unsteady turbulence problems

Scientists and engineers striving to create the next machine-age marvel--whether it be a more aerodynamic rocket, a faster race car, or a higher-efficiency jet...

Im Focus: Neues DFKI-Projekt SELFIE schlägt innovativen Weg in der Verifikation cyber-physischer Systeme ein

Vor der Markteinführung müssen neue Computersysteme auf ihre Korrektheit überprüft werden. Jedoch ist eine vollständige Verifikation aufgrund der Komplexität heutiger Rechner aus Zeitgründen oft nicht möglich. Im nun gestarteten Projekt SELFIE verfolgt der Forschungsbereich Cyber-Physical Systems des Deutschen Forschungszentrums für Künstliche Intelligenz (DFKI) unter Leitung von Prof. Dr. Rolf Drechsler einen grundlegend neuen Ansatz, der es Systemen ermöglicht, sich nach der Produktion und Auslieferung selbst zu verifizieren. Das Bundesministerium für Bildung und Forschung (BMBF) unterstützt das Vorhaben über drei Jahre mit einer Fördersumme von 1,4 Millionen Euro.

In den letzten Jahrzehnten wurden enorme Fortschritte in der Computertechnik erzielt. Ergebnis dieser Entwicklung sind eingebettete und cyber-physische...

Im Focus: „Künstliches Atom“ in Graphen-Schicht

Elektronen offenbaren ihre Quanteneigenschaften, wenn man sie in engen Bereichen gefangen hält. Ein Forschungsteam mit TU Wien-Beteiligung baut Elektronen-Gefängnisse in Graphen.

Wenn man Elektronen in einem engen Gefängnis einsperrt, dann benehmen sie sich ganz anders als im freien Raum. Ähnlich wie die Elektronen in einem Atom können...

Im Focus: X-ray optics on a chip

Waveguides are widely used for filtering, confining, guiding, coupling or splitting beams of visible light. However, creating waveguides that could do the same for X-rays has posed tremendous challenges in fabrication, so they are still only in an early stage of development.

In the latest issue of Acta Crystallographica Section A: Foundations and Advances , Sarah Hoffmann-Urlaub and Tim Salditt report the fabrication and testing of...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Neue Ideen für die Schifffahrt

24.08.2016 | Veranstaltungen

E-Health, E-Hygiene, IT-Management und IT-Sicherheit: Trends und Chancen für Kliniken und Praxen

24.08.2016 | Veranstaltungen

HTW Berlin richtet im September die 30. EnviroInfo aus

23.08.2016 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Neue Ideen für die Schifffahrt

24.08.2016 | Veranstaltungsnachrichten

Mikroskopieren mit einzelnen Ionen

24.08.2016 | Informationstechnologie

E-Health, E-Hygiene, IT-Management und IT-Sicherheit: Trends und Chancen für Kliniken und Praxen

24.08.2016 | Veranstaltungsnachrichten